Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a lit­tle less fu­ri­ous

Biotech VCs in the US con­tin­ued to steam along in the third quar­ter, rack­ing up $1.8 bil­lion in new in­vest­ments. That marks a slight drop from the same pe­ri­od a year ago, but 2016 is still out­strip­ping every­thing else on the record books aside from the siz­zling stretch through 2015.

The to­tal tots up as $5.5 bil­lion for the first nine months of the year, as VCs con­tin­ue to splurge on their port­fo­lio of new and ex­ist­ing drug de­vel­op­ers. By this point last year, the to­tal for the year topped $6 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.